ArticleCancer reports (Hoboken, N.J.)2025
Immune Reconstitution and Need for Booster Vaccinations Among Non-Transplant Childhood Cancer Survivors: A Single-Center Experience.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune Reconstitution and Need for Booster Vaccinations Among Non-Transplant Childhood Cancer Survivors: A Single-Center Experience.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWaning immunity from childhood vaccines can be more profound in pediatric patients following chemo/immunotherapy. Moreover, childhood cancer survivors (CCS) are at significantly increased risk for life-threatening infections. We implemented an institutional standard of practice (SOP) to assess immune reconstitution and provide recommendations for re-vaccination for non-transplant CCS.
methodsA lymphocyte mitogen proliferation panel was obtained at around 6 months off therapy to assess non-specific lymphocyte proliferation to phytohemagglutinin (PHA), concanavalin A (Con A), and pokeweed mitogen (PWM). Serologic concentrations of immunoglobulin G (IgG) antibodies were measured for hepatitis B (hepB) virus, tetanus toxoid, and Streptococcus pneumoniae. Booster vaccines were recommended for seronegative patients. Catch-up vaccines were recommended for CCS not previously up to date.
resultsAll evaluated patients were considered immune reconstituted at 6 months off therapy. Most patients (about 80%) were seronegative for hepB virus and S. pneumoniae, but nearly 100% retained immunity against tetanus. Most patients had positive seroconversion with a single booster vaccination with hepB (86%) and PPSV23 (76%). There were missed opportunities with each step of the institutional SOP due to provider omission with varying degrees depending on the provider.
conclusionsThis study suggests that most CCS are ready for re-immunization with inactivated vaccines by 6 months of therapy and underscores the need for boosters to optimize protection against vaccine-preventable infections. Future studies are needed to inform consensus guidelines adapted to patient age, underlying cancer diagnosis, and treatment intensity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.